Literature DB >> 12481843

The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations.

H C Cheng1.   

Abstract

INTRODUCTION: The Cheng-Prusoff equation (1973) is often applied to the determination of equilibrium dissociation constant (KB) of a competitive antagonist when the IC50 value is available. The purpose of this study is to illustrate that the slope function (K) of an agonist concentration-response curve is critical to the determination of KB values.
METHODS: The article describes new equations, which incorporate the slope function, consequently yielding more accurate estimation of KB values for antagonists, and tests them using simulated data. The value of KB was calculated according to the following new power equation: KB = IC50/(l + A(K)/Kp) = IC50/[l + (A/EC50)(K)], where IC50 is the concentration of the antagonist producing 50% inhibition, A is the concentration of the agonist against which the IC50 is being determined and KP is the apparent equilibrium dissociation constant of the agonist.
RESULTS: The new equation is the same as the Cheng-Prusoff equation when the slope function K is exactly unity. Application of the equation avoids errors inherent in the use of the Cheng-Prusoff equation when the slope function of the agonist concentration-response curve deviates from unity. The new equation was applicable to slope functions less than, equal to or greater than unity. All inhibition curves have a negative slope function of 1, indicating that there is only one single receptor population even though different slope functions of agonist concentration-response curves are involved. The importance of the power function in the Schild plot is illustrated by using the equation: log (x(K) - 1) = log B - log KB, where x is the concentration ratio and B is the concentration of the antagonist. DISCUSSION: This investigation illustrates the application of six power equations for accurate estimation of KB values covering situations with different slope functions of the agonist concentration-response curves.

Mesh:

Year:  2001        PMID: 12481843     DOI: 10.1016/s1056-8719(02)00166-1

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  45 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

3.  Peptide ligands that use a novel binding site to target both TGF-β receptors.

Authors:  Lingyin Li; Brendan P Orner; Tao Huang; Andrew P Hinck; Laura L Kiessling
Journal:  Mol Biosyst       Date:  2010-10-04

4.  The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Authors:  Susanne Horner; Kirsten Menke; Caren Hildebrandt; Matthias U Kassack; Peter Nickel; Heiko Ullmann; Martyn P Mahaut-Smith; Günter Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-13       Impact factor: 3.000

5.  Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Authors:  Ying Chen; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Mrudula Pullambhatla; James J Fox; Mark Castanares; Shawn E Lupold; John W Babich; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

6.  Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo.

Authors:  Denise Garcia; Patrick Nasarre; Ingrid V Bonilla; Eleanor Hilliard; Yuri K Peterson; Laura Spruill; Anne-Marie Broome; Elizabeth G Hill; Jason T Yustein; Shikhar Mehrotra; Nancy Klauber-DeMore
Journal:  Ann Surg Oncol       Date:  2019-09-12       Impact factor: 5.344

7.  Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.

Authors:  Bennett Ma; Bin Luo; Danielle H Euler; Tara E Cusick; Gregg Wesolowski; Helmut Glantschnig; Le T Duong; Yangsi Ou; Steven S Carroll; Laura S Lubbers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-20       Impact factor: 3.000

8.  Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.

Authors:  Wei Zhou; Yiping Li; Jinhua Song; Chenglong Li
Journal:  Anal Biochem       Date:  2019-08-31       Impact factor: 3.365

9.  Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; David L Stevens; Essie Komla; Dana E Selley; William L Dewey; Hamid I Akbarali; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2018-07-23       Impact factor: 4.418

10.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding.

Authors:  R Z Cer; U Mudunuri; R Stephens; F J Lebeda
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.